ClinicalTrials.gg
Not yet recruitingNCT07495839EQUI-ADDICTUpdated Nov 2, 2026

The Impact of Equine-Assisted Therapy on Mental Health and Addictive Behaviors in Patients Receiving Addiction Treatment

An interventional study of Equine mediation in Equine-assisted Therapy, Addiction and Recidivism, sponsored by Hopital La Musse. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Hopital La Musse · Not applicable, Interventional, and Treatment

How we know

Updated Nov 2, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Addiction is a major public health issue. According to the World Health Organization (2024), approximately 400 million people worldwide suffer from alcohol- or drug-related disorders, resulting in nearly 3.2 million deaths per year. In France, the situation is also cause for concern: approximately three million people engage in risky alcohol consumption, thirteen million smoke daily, and nearly one and a half million use illicit drugs, primarily cannabis.

Addiction, defined by the National Institute on Drug Abuse (NIDA) as a chronic, relapsing brain disorder, is characterized by the compulsive pursuit and use of a substance despite knowledge of its harmful effects. Its development depends on multiple factors: personal (trauma, psychiatric disorders, genetic predispositions), environmental (stress, isolation, family context), and those related to the substance itself (addictive potential). The diagnosis of substance use disorders is based on 11 criteria defined in the *Diagnostic and Statistical Manual of Mental Disorders* (DSM-5), the main ones being: loss of self-control, interference of substance use with academic or occupational activities, continued use despite awareness of the problems it causes, and a new central criterion, craving, defined as an irresistible urge to use, which serves as both a symptom and a diagnostic and prognostic marker because it is a predictor of relapse. The cumulative total of criteria allows the disorder to be classified as mild (2-3), moderate (4-5), or severe (≤ 6). Since the 2020 health crisis, researchers have observed an increase in the use of psychoactive substances, particularly among vulnerable populations. Despite public policy efforts and treatment programs, relapses remain common after treatment, affecting 60 to 70% of patients within six months of their hospitalization. This phenomenon is also observed at La Musse Hospital, where many patients admitted to the nutrition and alcoholism unit express a sense of emptiness upon returning home: a void in relationships, therapy, and daily activities. This feeling often contributes to a return to substance use.

To address these relapses, this study aims to evaluate the impact of a post-hospitalization equine-assisted therapy program on the mental health and addictive behaviors of patients receiving addiction treatment. Already used at La Musse Hospital as part of the care pathway, equine-assisted therapy is based on the interaction between the patient and the horse in a therapeutic setting. Several studies have demonstrated the benefits of this approach on emotional regulation, self-confidence, stress management, and overall well-being.

This prospective, single-center, interventional study will include twenty-two patients who have been hospitalized at least once in the nutrition and alcoholism unit at La Musse Hospital or another facility. Participants will be randomly assigned to either a group receiving post-hospitalization equine-assisted therapy or a control group.

02

Conditions studied

  • Equine-assisted Therapy
  • Addiction
  • Recidivism
  • Addictive Behaviors
  • Mental Health

Keywords

  • Equine mediation
  • Addiction
  • Recidivism
  • Addictive behavior
  • Mental health
03

In context

Behavior, Addictive

522 studies on the registry are indexed under Behavior, Addictive; 125 are open to participants now.

This study's planned enrollment of 22 is below the median of 62 across 399 interventional studies indexed under Behavior, Addictive.

Browse Behavior, Addictive studies →

Lead sponsor

Hopital La Musse is the lead sponsor of 14 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients over the age of 18,
  • Patients who have completed detoxification and have been hospitalized at least once in the nutrition and alcoholism unit at La Musse Hospital or at another facility,
  • Patients with an addiction to a psychoactive substance (e.g., alcohol, tobacco, cannabis),
  • Able to participate in animal-assisted therapy sessions,
  • Ability to understand instructions during sessions,
  • Enrolled in the social security system.

Exclusion criteria

Exclusion Criteria:

  • Patients with a behavioral addiction not involving substances (e.g., gambling, sexual addiction),
  • Patients who have not yet completed detoxification,
  • Patients under legal guardianship,
  • Patients currently undergoing other animal-assisted therapy,
  • Allergies to horses,
  • Other serious medical conditions that may interfere with participation in the sessions.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Patients in the experimental group will receive 22 sessions of equine-assisted therapy over a 24-week period

    Other: Equine mediation

  • No intervention
    Control Group

    Patients in the control group will not receive equine-assisted therapy sessions but will only undergo various follow-up assessments

Interventions

  • OtherEquine mediation

    Patients in the experimental group will receive 22 sessions of equine-assisted therapy over a 24-week period (Figure 2). The objective of this protocol is to provide a phased transition toward a gradual return to their daily lives. To this end, two equine-assisted therapy sessions per week will be conducted for 1 month (8 sessions), followed by one session per week for 2 months (8 sessions), and finally one session every two weeks for 3 months (6 sessions). Each session will last 1 hour and 30 minutes, with groups of 4 patients, led by 2 professionals from the equine therapy center at La Musse Hospital.

06

What researchers measure

Primary outcomes

  1. The score on the Craving Experience Questionnaire

    The score on the Craving Experience Questionnaire (CEQ-F). This questionnaire retrospectively assesses the intensity and frequency of cravings over a specific time period. The CEQ allows for the assessment of cravings for a variety of substances, including alcohol, cigarettes, drugs, or food. The CEQ exhibits excellent psychometric properties (May et al., 2014). This questionnaire enables the calculation of a craving intensity score for a specific substance or food based on the 11 intensity items. Each item is rated on a scale from 0 ("Not at all") to 10 ("Extremely"). Summing these 11 scores yields a total craving intensity score ranging from 0 to 110. The higher the score, the more intense the participant's craving is considered to be. Additionally, the craving frequency score obtained by the CEQ can be calculated by adding the values obtained for the 11 items corresponding to frequency. Each item in this section is rated on a

    Time frame: at the start of the program (week 1), then 5 weeks, 13 weeks, 25 weeks, and 37 weeks after the start of the program.

Secondary outcomes

  1. The total score on the Beck Depression Inventory

    The Beck Depression Inventory is one of the most widely used screening tools for measuring the severity of depression in adults and adolescents over the age of 13. It consists of 21 items related to depressive symptoms (e.g., hopelessness and irritability), cognitions (e.g., guilt or feelings of being punished), and physical symptoms (e.g., fatigue, weight loss, and loss of interest in sex). Each item is rated on a severity scale ranging from 0 to 3, with a total score ranging from 0 to 63. The higher the score, the more severe the depression.

    Time frame: at the start of the program (week 1), then 5 weeks, 13 weeks, 25 weeks, and 37 weeks after the start of the program.

  2. The total score on the Beck Anxiety Inventory

    As with depression, the Beck Anxiety Inventory consists of 21 items corresponding to anxiety symptoms identified in large clinical samples (e.g., panic disorder and generalized anxiety disorder). Each item is rated on a severity scale ranging from 0 (not at all) to 3 (very much), with a total score ranging from 0 to 63. The higher the score, the more severe the anxiety.

    Time frame: at the start of the program (week 1), then 5 weeks, 13 weeks, 25 weeks, and 37 weeks after the start of the program.

  3. The number of relapses

    The number of relapses recorded in the logbook, which the patient fills out themselves throughout the study (weekly), thereby assessing their addictive behaviors

    Time frame: Each week, up to 37 weeks

  4. The number, intensity, and duration of self-reported cravings

    The number, intensity, and duration of self-reported cravings, recorded in the logbook completed by the patient throughout the study

    Time frame: Each week, up to 37 weeks

  5. Scores on the WHOQOL-BREF quality of life questionnaire

    With 26 items, the WHOQOL-BREF is a shortened version of the WHOQOL-100, an instrument designed to measure subjective quality of life. This is defined as an individual's perception of their own life situation within the context of their culture and value system, as well as in relation to personal goals, expectations, evaluation criteria, and interests. The WHOQOL-BREF was developed as a generic quality of life questionnaire and is therefore not limited to specific areas of application. The questionnaire is completed by the respondent. The WHOQOL-BREF covers the four domains of physical health, psychological well-being, social relationships, and environment. Items are rated on a five-point scale (from "not at all" to "somewhat no," "about," "most of the time," to "completely"). The scales exhibit very high internal consistency. The WHOQOL has received widespread international support and is available in multiple languages. It is validated and reliable.

    Time frame: at the start of the program (week 1), then 5 weeks, 13 weeks, 25 weeks, and 37 weeks after the start of the program.

  6. Scores on the WHO-5 Well-Being Questionnaire

    The WHO-5 is a measure of mental well-being consisting of five statements referring to the past two weeks. Each statement is rated on a 6-point scale, with higher scores indicating better mental well-being. The instrument has been translated into more than 30 languages.

    Time frame: at the start of the program (week 1), then 5 weeks, 13 weeks, 25 weeks, and 37 weeks after the start of the program.

  7. Physical health scores

    The 6-minute walk test (6MWT), Timed Up and Go Test (TUG) and the numerical Pain Scale.

    Time frame: at the start of the program (week 1), then 5 weeks, 13 weeks, 25 weeks, and 37 weeks after the start of the program.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Apr 2028, 16 months later.

Of 148 non-industry interventional studies with no phase under Behavior, Addictive, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 42. This study's planned 16 months is below that.

Counting every sponsor, half of 156 studies reached it within 26 months; a quarter within 10 and three quarters within 42.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → Nov 2026, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2026
First posted
Mar 27, 2026
StartEst.
Nov 12, 2026was Apr 2026
Primary completionEst.
Apr 1, 2028
CompletionEst.
Aug 31, 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 1, 2026→Nov 12, 2026
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Start date Apr 1, 2026→Nov 12, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07495839
Lead sponsor
Hopital La Musse
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Nov 12, 2026 (estimated)
Primary completion
Apr 1, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Héloïse BAILLET, Dr
Contact
h.baillet@hlrs-lamusse.net
+33(0)232293047

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion